Drug Trial Radar · NCT01764243
Safety and Efficacy of MT-4666
Last checked: Nov 20, 2026Latest source record: Sep 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
450
Actual
Start
Nov 2012
Primary completion
Jun 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate Alzheimer's disease.
Conditions
- Alzheimer's Disease
Interventions
MT-4666Drug
low dose, high dose
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in ADAS-cog-13Time frame: Baseline and Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Kanto, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.